Search results

Meet our scientist Gesine Paul-Visse to learn what happens at the interface where the brain and the body meet: the blood-brain barrier. Here, a very specialized cell, the pericyte, protects the brain and responds strongly to disease. Gesine Paul-Visse leads Translational Neurology, one of MultiPark’s research groups. As both a neurologist and a researcher, she has focused on neurodegeneration for

https://www.multipark.lu.se/article/meet-our-scientists-podcast-gesine-paul-visse-about-brains-frontline - 2026-01-03

Researchers at MultiPark have uncovered in mice how the protein TDP-43, known for its role in several neurodegenerative diseases, disrupts the hypothalamus, the brain’s key center for metabolic control. Their study sheds new light on the role of TDP-43 in metabolic and psychiatric symptoms shared across frontotemporal dementia, Huntington’s disease, and ALS – findings that could support the develo

https://www.multipark.lu.se/article/protein-mismanagement-brains-control-center-fuels-early-symptoms-neurodegenerative-diseases - 2026-01-03

An experimental study from Lund University reveals for the first time that different Parkinson’s medications affect brain activity in distinct ways. This could explain why some patients develop impulsive and compulsive behaviors as a result of their treatment. The findings have been published in NPJ Parkinson’s Disease. Upon receiving treatment for their motor symptoms, many patients with Parkinso

https://www.multipark.lu.se/article/brain-activation-pattern-behind-impulsivity-parkinsons-treatment-discovered - 2026-01-03

Meet our scientist, Dr. Niklas Mattsson-Carlgren! He explains why studying biomarkers is essential to advancing Alzheimer’s research. Niklas Mattsson-Carlgren is part of the Clinical Memory Research group, a leading centre in the development and evaluation of novel biomarkers for Alzheimer’s disease. In this podcast episode, he discusses why biomarker research is key not only to detecting but also

https://www.multipark.lu.se/article/meet-our-scientists-podcast-niklas-mattsson-carlgren-about-biomarkers-and-future-alzheimers - 2026-01-03

With over 15 research groups dedicated to Alzheimer’s disease research, MultiPark’s goal is to understand the origins of the disease, develop early diagnostics, and improve treatments. The multidisciplinary approach sheds light on the disease from several angles, bridging basic research with clinical investigations. Here are five projects. September is World Alzheimer’s Month. Globally, around 40

https://www.multipark.lu.se/article/alzheimers-awareness-five-research-projects-shaping-future-understanding-diagnosis-and-care - 2026-01-03

For decades, large stretches of human DNA were dismissed as ‘junk’ and considered to serve no real purpose. In a new study in Cell Genomics, researchers at Lund University in Sweden show that the repetitive part of the human genome plays an active role during early brain development and may also be relevant for understanding brain diseases. DNA carries the complete set of instructions an organism

https://www.multipark.lu.se/article/why-repetitive-dna-matters-human-brain-evolution-and-disease - 2026-01-03

Enormous amounts of data about Alzheimer’s Disease have been generated from clinical studies so far. Still, the molecular drivers of Alzheimer’s Disease are largely unknown. With the TAU-TIME project, Jacob Vogel aims to advance knowledge by developing an AI tool that brings together known biological mechanisms with data from patients with the disease. Recent funding from the European Research Cou

https://www.multipark.lu.se/article/time-unite-lab-and-clinic-15-million-eu-build-ai-model-alzheimers-disease - 2026-01-03

Early diagnosis is key to receiving proper care and advancing research on future therapies for neurodegenerative diseases such as Parkinson’s and dementia with Lewy bodies. New research from Skåne University Hospital and Lund University shows that combining a simple smell test with advanced spinal fluid analysis can predict these diseases with high accuracy, while sparing nearly half of patients f

https://www.multipark.lu.se/article/smell-test-cuts-need-invasive-parkinsons-screening - 2026-01-03

Researchers at Lund University in Sweden have developed a digital cognitive test for diagnosing Alzheimer's disease that is intended for use in primary care. “This digital test, which patients perform on their own with minimal involvement from healthcare personnel, improves the primary care physician's ability to determine who should be further examined by blood tests for Alzheimer's pathology ear

https://www.multipark.lu.se/article/new-digital-cognitive-test-diagnosing-alzheimers-disease - 2026-01-03

What if brain diseases could be cured by turning on the proper genes? Meet our scientist, Professor Cecilia Lundberg! She explains how gene therapy may complement cell therapies to combat Parkinson’s disease. Cecilia Lundberg is head of the CNS Gene Therapy Research Group and has spent her whole career developing cutting-edge tools that may be used in future therapies to slow down or cure neurodeg

https://www.multipark.lu.se/article/meet-our-scientists-podcast-cecilia-lundberg-about-gene-workshop - 2026-01-03

Have you ever wondered what the journey of someone living with Parkinson’s disease looks like? Meet our scientist, Professor Per Odin! He shares his experiences of the bumpy road faced by patients he has supported over the years, both in healthcare and in research studies. Parkinson’s disease is a long, challenging course; one that science works tirelessly to understand, where halting neurodegener

https://www.multipark.lu.se/article/meet-our-scientists-podcast-odin-about-parkinsons-journey - 2026-01-03

In a study led by Lund University and the Amsterdam University Medical Center, researchers used PET to analyse aggregates of tau pathology in more than 12,000 people from all over the world. The study – the largest ever of its kind – examines the connection between genetic predisposition, gender and age in relation to tau pathology in Alzheimer’s disease. The study is published in Nature Neuroscie

https://www.multipark.lu.se/article/largest-ever-taupet-study-alzheimers-deepens-understanding-disease - 2026-01-03

With an approval rate of just 17 %, this year’s Swedish Research Council grants were harder than usual to secure. Still, several of MultiPark’s group leaders were awarded major grants in Medicine and Health 2025. Receiving grants from the Swedish Research Council is seen as a mark of quality and an important step in advancing an independent research group. Recently, six MultiPark researchers were

https://www.multipark.lu.se/article/multipark-scientists-awarded-prestigious-vr-consolidator-grant - 2026-01-03

Nine researchers from MultiPark have been listed as Highly Cited Researchers by Clarivate, highlighting their significant global research impact. Clarivate acknowledges researchers whose publications rank among the top 1% most cited in their fields over the past eleven years. The selected scientists have published several highly-cited papers. Congratulations to Oskar Hansson, Shorena Janelidze, Sa

https://www.multipark.lu.se/article/multipark-researchers-recognized-clarivates-highly-cited-list - 2026-01-03

Recently, MultiPark opened its doors to the local Parkinson’s Association, who were invited behind the scenes to see how research on their condition is conducted. Here are some of the laboratories that were visited. Today’s basic research on brain disorders such as Parkinson’s may be the starting point for tomorrow’s treatments. This may explain the participants’ deep interest in MultiPark’s exper

https://www.multipark.lu.se/article/journey-discovery-research-multipark-opens-labs-parkinsons-association - 2026-01-03

How do you stop Alzheimer’s disease without a simple way to diagnose it? It’s a real chicken and egg problem, as I wrote last year on TGN. Discovering a treatment for Alzheimer’s requires lots of clinical trials for new drugs—but it’s difficult to enroll participants without a way to identify people who have the disease early enough for potential treatments to work. Read the full article here

https://www.multipark.lu.se/article/unexpected-way-we-might-one-day-diagnose-alzheimers - 2026-01-03

A new study confirms that a simple blood test can reveal whether there is accelerating nerve cell damage in the brain. The researchers analysed neurofilament light protein (NFL) in blood samples from patients with Alzheimer’s disease. Recently published in JAMA Neurology, the study suggests that the NFL concentration in the blood could be able to indicate if a drug actually affects the loss of ner

https://www.multipark.lu.se/article/more-evidence-blood-tests-can-detect-risk-alzheimers - 2026-01-03

In recent years, it has become increasingly clear to researchers that the protein galectin-3 is involved in inflammatory diseases in the brain. A study led by researchers at Lund University in Sweden now shows the de facto key role played by the protein in Alzheimer’s disease. When the researchers shut off the gene that produces this protein in mice, the amount of Alzheimer’s plaque and the inflam

https://www.multipark.lu.se/article/researchers-block-protein-plays-key-role-alzheimers-disease - 2026-01-03

Daniella was awarded the prize for "successful effort as a young researcher and group leader". Link to Jeanssons Foundation website (in Swedish)

https://www.multipark.lu.se/article/daniella-ottosson-receives-prize-jeanssons-foundation - 2026-01-03

The Future Faculty is proud to present the 2019 Minerva Award to Tomas Deierborg, associate professor at the Department of Experimental Medical Sciences.The Minerva award selection committee's motivation for the choice is: "The core values of the Minerva award are honesty, trust, fairness, respect, responsibility and courage. From the nominations it is obvious that Tomas Deierborg possess all thes

https://www.multipark.lu.se/article/minerva-award-tomas-deierborg - 2026-01-03